Oxford BioMedica (OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.
They have built a sector-leading lentiviral vector delivery platform, called LentiVector®, which they uses to develop in vivo and ex vivo products both in-house and with partners.
The have created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.
They also have a number of partnerships, including with Novartis, Sanofi, GSK and Orchard Therapeutics, where they have long-term economic interests in other potential gene and cell therapy products. The company is based across four locations in Oxfordshire.
The company was founded in 1995 as a spin-out from the Department of Biochemistry at University of Oxford.